News
-
-
-
PRESS RELEASE
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for COPD patients based on pivotal phase 3 results in adults with elevated eosinophils, marking a new treatment approach for COPD -
PRESS RELEASE
Communiqué de presse : Le Dupixent devient le tout premier biomédicament approuvé au Japon pour le traitement de la BPCO
Le Dupixent est le premier biomédicament approuvé au Japon pour traiter la BPCO, avec des résultats positifs provenant d'études de phase III. Paris, New York - 28 mars 2025 -
-
-
-
-
PRESS RELEASE
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
DBV Technologies secures financing of up to $306.9 million (€284.5 million) to advance Viaskin Peanut Patch through FDA submission and US commercial launch. Investors include MPM BioImpact, Adage Capital Management, Janus Henderson Investors, and more -